Scholarlink

HRD is a useful biomarker, positive in approximately 50–60% of advanced ovarian cancer. Since maintenance therapy with PARP inhibitors offers significant survival benefit, especially in HRD-positive tumors, physicians treating ovarian cancer patients must accurately and appropriately identify HRD-positive ovarian cancer. However, HRD assays also have several limitations in identifying HRD-positive ovarian cancer, including issues with the MyChoice® GIS cutoff value, the existence of alternative evaluation methods other than MyChoice®, and problems related to tumor heterogeneity and changing HRD score over time. Furthermore, we must recognize that HRD testing is also a genetic test that can help identify HBOC.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Current Status and Problems of HRD Testing in Ovarian Cancer Treatment

  • 章节

  • 发表日期：

    2026年

查看全文
  • Koji Nishino

摘要

HRD is a useful biomarker, positive in approximately 50–60% of advanced ovarian cancer. Since maintenance therapy with PARP inhibitors offers significant survival benefit, especially in HRD-positive tumors, physicians treating ovarian cancer patients must accurately and appropriately identify HRD-positive ovarian cancer. However, HRD assays also have several limitations in identifying HRD-positive ovarian cancer, including issues with the MyChoice® GIS cutoff value, the existence of alternative evaluation methods other than MyChoice®, and problems related to tumor heterogeneity and changing HRD score over time. Furthermore, we must recognize that HRD testing is also a genetic test that can help identify HBOC.